as defined by the National Cholesterol Education Program (NCEP) (1). Clinical trials demonstrate that the incidence of heart disease is reduced when patients with high blood cholesterol are treated with diet and drugs (2). The NCEP has recommended that all patients older than 20 years have their cholesterol concentration measured at least every five years (3). This recommendation has created a need for accurate and widely available cholesterol testing in our society.
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We report the accuracy, imprecision, total analytical errors, and patient misclassification errors for cholesterol measured from capillary whole blood, venous whole blood, and venous plasma samples by five devices used in public cholesterol screening environments: Refiotron, Vision, Ektachem DT-60, QuickRead, and Liposcan. None of the methods met the National Cholesterol Education Program (NCEP) performance recommendations of 3% CV with 3% bias. The Vision and Reflotronmethods used with venous samples gave individual results with total errors consistent with a combined CV and bias in the 4-5% range; capillary blood samples had total errors >5% (combined CV and bias criteria). The DT-60 performance was near the 5% total error criterion for capillary samples and was >5% for venous samples. Misclassification of individuals into desirable or referral groups for venous samples was as great as 5.1% for the DT-60, 5 .7% for the Vision, and 7.1% for the Reflotron. Misclas- Heart disease is a major health problem in the United States. One of the modifiable risk factors associated with heart disease is high blood concentrations of cholesterol. An estimated 36% of the population has hypercholesterolemia, as defined by the National Cholesterol Education Program (NCEP) (1). Clinical trials demonstrate that the incidence of heart disease is reduced when patients with high blood cholesterol are treated with diet and drugs (2) . The NCEP has recommended that all patients older than 20 years have their cholesterol concentration measured at least every five years (3) . This recommendation has created a need for accurate and widely available cholesterol testing in our society.
Several compact devices that measure total cholesterol from capillary blood samples are now available to make cholesterol testing more accessible to the public.
The Laboratory Standardization
Panel of the NCEP recommends that the accuracy of cholesterol testing be within 3% of the result by the Reference Method at the Centers for Disease Control and that imprecision (CV) be within ± 3% (4). These guidelines apply to all settings in which cholesterol is meastired, including public screenings and physicians' offices, where desk-top devices are likely to be used, and to all sample types, including capillary blood. We report here the accuracy, imprecision, total analytical errors, and misclassification rates of cholesterol measured in capillary whole blood, venous whole blood, and venous plasma by five devices used in public cholesterol screening environments.
Materials and Methods
The cholesterol-nicasuring devices tested were Refiotron ( Three frozen pooled human serum samples were assayed in duplicate at the beginning and end of each of 10 days (n = 40, Reflotron), 9 days (n = 36, Vision), or 6 days (n = 24, DT-60, and QuickRead). 
Pools were

#{149}4.i -10
#{149} .. The importance of evaluating total error is illustrated graphically in the bias plots (Figures 1-4) , which show that a large proportion of subjects' results differ substantially from the correct cholesterol values. As an example, let us consider venous plasma measurements with the Reflotron analyzer: the average bias was -0.3% and Fig. 3 
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denote the test mean and reference mean, respectively, for the ith subject. Next, construct the ratio of means for each of the n subjects as overlap index, no significant differences were found between the commercial kit and a common turbidimetric assay for diagnosing patients with acute pancreatitis; both methods performed satisfactorily.
Enzymatic testing is often used to evaluate patients with acute abdominal distress and possible pancreatitis (1). Although amylase (EC 3.2.1.1) has been historically used for this purpose, the clinical nonspecifIcity of total amylase concentrations has often been emphasized (2, 3) and other assays have been developed to improve on the specificity of the diagnosis (3) (4) (5) . Recently, we were able to confirm the diagnosis of acute pancreatitis by serum pancreatic lipase (triacylglycerol acylhydrolase, EC 3.1.1.3) by using a turbidimetric determination (6-8). However, some analytical shortcomings (narrow measuring range, low sensitivity in the subnormal range, and negative activities in rare specimens containing low lipase activities) limit the reliability of turbidimetric measurement of lipase activity and discourage the use of this assay as a first diagnostic test for pancreatic disease (9). When we simplified the lipase
